Mirikizumab is a medication being studied for its effectiveness in treating children and adolescents with moderate-to-severe ulcerative colitis or Crohn’s disease. This trial aims to understand how well mirikizumab works over a long period and to ensure it is safe for young patients with these conditions.

Ulcerative Colitis Chronic – A long-term condition affecting the colon, characterized by inflammation and ulcers on the inner lining of the large intestine. Symptoms often include abdominal pain, diarrhea, and rectal bleeding. The disease typically progresses with periods of flare-ups and remission. Over time, the inflammation can lead to complications such as narrowing of the colon or increased risk of colon cancer.

Inflammatory Bowel Diseases – A group of disorders that cause chronic inflammation in the digestive tract. The two main types are Crohn’s disease and ulcerative colitis. Symptoms can include persistent diarrhea, abdominal pain, and weight loss. The inflammation can affect different parts of the digestive tract, leading to various complications over time.

Crohn’s Disease – A chronic inflammatory condition that can affect any part of the gastrointestinal tract, from the mouth to the anus. It often causes abdominal pain, severe diarrhea, fatigue, and malnutrition. The inflammation can spread deep into the layers of affected bowel tissue. The disease can lead to complications such as strictures or fistulas.

Ulcerative Colitis – A chronic inflammatory condition specifically affecting the colon and rectum. It is characterized by continuous inflammation of the colon lining, leading to ulcers. Symptoms include frequent diarrhea, abdominal pain, and rectal bleeding. The disease progresses with alternating periods of active symptoms and remission.